A citation-based method for searching scientific literature

Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Shuguang Xu, Wenxian Wang, Chunwei Xu, Xingliang Li, Junhui Ye, Youcai Zhu, Ting Ge. BMC Cancer 2019
11
100

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
100


Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
Karim Rihawi, Marika Cinausero, Michelangelo Fiorentino, Stefania Salvagni, Stefano Brocchi, Andrea Ardizzoni. J Thorac Oncol 2018
3
100

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
Shuang Ren, Sisi Huang, Xinqing Ye, Luhuai Feng, Yang Lu, Chaonan Zhou, Juan Zhao, Tingting He, Junwei Wang, Bixun Li. Cancer Treat Res Commun 2021
3
100

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, Mark Bailey, Alexa B Schrock, Justin F Gainor, Lorin A Ferris, Mari Mino-Kenudson, Vincent A Miller, Anthony J Iafrate,[...]. J Thorac Oncol 2017
59
100

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch,[...]. Clin Cancer Res 2012
132
100

ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1.
Timothy Fielder, Jordan Butler, Geraldine Tierney, Mikaela Holmes, Ki Yuk Lam, Laveniya Satgunaseelan, Andrew J Colebatch, Annabelle Mahar, Ruta Gupta, Sandra O'Toole,[...]. Pathology 2021
1
100

Recent Advances in Targeting ROS1 in Lung Cancer.
Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
121
100


Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
D Ross Camidge, Dong-Wan Kim, Marcello Tiseo, Corey J Langer, Myung-Ju Ahn, Alice T Shaw, Rudolf M Huber, Maximilian J Hochmair, Dae Ho Lee, Lyudmila A Bazhenova,[...]. J Clin Oncol 2018
78
100

ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.
Aline F Fares, Benjamin H Lok, Tong Zhang, Michael Cabanero, Sally C M Lau, Tracy Stockley, Devalben Patel, Penelope A Bradbury, Adrian Sacher, Kazuhiro Yasufuku,[...]. Lung Cancer 2020
3
100

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, Ryohei Katayama, Yuki Shimizu, Viola W Zhu, Thomas Yang Sun, Heather A Wakelee, Russell Madison, Alexa B Schrock,[...]. Clin Cancer Res 2020
27
100

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
Xinghao Ai, Qiming Wang, Ying Cheng, Xiaoqing Liu, Lejie Cao, Jianhua Chen, Xiaorong Dong, Jianying Zhou, Yun Fan, Cheng Huang,[...]. J Thorac Oncol 2021
2
100

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
238
100

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Go Makimoto, Kiichiro Ninomiya, Kazuya Nishii, Hisao Higo, Chihiro Ando, Sachi Okawa, Takamasa Nakasuka,[...]. Cancer Sci 2021
6
100


Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L Lockerman, Sumie Koike, Alice T Shaw, Jeffrey A Engelman, Naoya Fujita. Clin Cancer Res 2015
123
100

Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
237
100

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
3
100

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).
Alain Charest, Keara Lane, Kevin McMahon, Julie Park, Elizabeth Preisinger, Helen Conroy, David Housman. Genes Chromosomes Cancer 2003
142
100

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
85
100

Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li,[...]. Mol Oncol 2020
4
100

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
72
100

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
14
100

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
E Dudnik, A Agbarya, R Grinberg, A Cyjon, J Bar, M Moskovitz, N Peled. Clin Transl Oncol 2020
2
100

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
118
100

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
Sha Fu, Ying Liang, Yong-Bin Lin, Fang Wang, Ma-Yan Huang, Zi-Chen Zhang, Jing Wang, Wen-Jian Cen, Jian-Yong Shao. PLoS One 2015
13
100

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
98
100

3
100

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Yun Shu, Hui Li, Hongjuan Shang, Jun Chen, Xiaoxing Su, Wei Le, Yan Lei, Liming Tao, Cailiang Zou, Wendy Wu. Onco Targets Ther 2020
2
100

Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
Maisam Makarem, Doreen A Ezeife, Adam C Smith, Janice J N Li, Jennifer H Law, Ming-Sound Tsao, Natasha B Leighl. Curr Oncol 2021
2
100

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
Jing Zheng, He Cao, Yuping Li, Chuangzhou Rao, Te Zhang, Jiayou Luo, Dongqing Lv, Yanping Zhu, Jianya Zhou, Jianying Zhou. Lung Cancer 2020
5
100

Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.
Stephen Q Wong, Jason Li, Angela Y-C Tan, Ravikiran Vedururu, Jia-Min B Pang, Hongdo Do, Jason Ellul, Ken Doig, Anthony Bell, Grant A MacArthur,[...]. BMC Med Genomics 2014
164
100


The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
Hyun Jung Jun, Hannah Johnson, Roderick T Bronson, Sebastien de Feraudy, Forest White, Alain Charest. Cancer Res 2012
63
100


Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Carol C Cheung, Adam C Smith, Roula Albadine, Gilbert Bigras, Anna Bojarski, Christian Couture, Jean-Claude Cutz, Weei-Yuan Huang, Diana Ionescu, Doha Itani,[...]. Lung Cancer 2021
5
100

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations.
Richard S P Huang, Amanda Gottberg-Williams, Panhia Vang, Shoua Yang, Nicholas Britt, Jaspreet Kaur, James Haberberger, Natalie Danziger, Clarence Owens, Sara E Beckloff,[...]. JTO Clin Res Rep 2020
1
100

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Tejas Patil, Derek E Smith, Paul A Bunn, Dara L Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, D Ross Camidge, Robert C Doebele. J Thorac Oncol 2018
62
100

Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report.
Ryota Otoshi, Akimasa Sekine, Koji Okudela, Takuma Katano, Masato Asaoka, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu, Eri Hagiwara, Ogura Takashi. Mol Clin Oncol 2020
2
100

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Sergi Clavé, Natalia Rodon, Lara Pijuan, Olga Díaz, Marta Lorenzo, Pedro Rocha, Álvaro Taus, Remei Blanco, Joaquim Bosch-Barrera, Noemí Reguart,[...]. Clin Lung Cancer 2019
17
100

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
121
100

A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
Arnaud Uguen, Ulrike Schick, Gilles Quéré. J Thorac Oncol 2017
12
100

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
319
100

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D Moro-Sibilot, N Cozic, M Pérol, J Mazières, J Otto, P J Souquet, R Bahleda, M Wislez, G Zalcman, S D Guibert,[...]. Ann Oncol 2019
62
100

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi,[...]. J Thorac Oncol 2018
50
100

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
100

ROS1 fusions in Chinese patients with non-small-cell lung cancer.
W Cai, X Li, C Su, L Fan, L Zheng, K Fei, C Zhou, C Manegold, G Schmid-Bindert. Ann Oncol 2013
64
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.